ANDS has been hyping an ANA598 partnership for awhile now. If they were truly drawing legitimate interest from big pharma, I don't think they would need to all of a sudden turn to Lazard for help. This news isn't surprising, however, insofar as the results to date for the drug have been so-so and the drug itself isn't even in one of the HCV classes that most expect to form the backbone of HCV therapy in the future (PIs and/or nukes, not non-nukes).